uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
about
Translational progress on tumor biomarkersHER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancerExosome secretome and mediated signaling in breast cancer patients with nontuberculous mycobacterial diseaseuPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis.A Joint Bayesian Model for Integrating Microarray and RNA Sequencing Transcriptomic Data.High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patientsInsulin-like growth factor binding protein-3 links obesity and breast cancer progression.Serpin E2 promotes breast cancer metastasis by remodeling the tumor matrix and polarizing tumor associated macrophages.Role of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases.Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.The PeptideAtlas of the Domestic Laying Hen.Hispolon suppresses migration and invasion of human nasopharyngeal carcinoma cells by inhibiting the urokinase-plasminogen activator through modulation of the Akt signaling pathway.Secretome profiling of oral squamous cell carcinoma-associated fibroblasts reveals organization and disassembly of extracellular matrix and collagen metabolic process signatures.RNF11 sequestration of the E3 ligase SMURF2 on membranes antagonizes SMAD7 down-regulation of transforming growth factor β signaling.Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.The influence of platelet membranes on tumour cell behaviour.Number of Intratumoral T Lymphocytes Is Associated With Lymph Node Size, Lymph Node Harvest, and Outcome in Node-Negative Colon Cancer.Urokinase plasminogen activator protects cardiac myocytes from oxidative damage and apoptosis via hOGG1 induction.Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer.TIPE3 protein promotes breast cancer metastasis through activating AKT and NF-κB signaling pathways.HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells.Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.The Urokinase/Urokinase Receptor System in Mast Cells: Effects of its Functional Interaction with fMLF ReceptorsIncreased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas.The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas.The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges.Identification of cancer genes that are independent of dominant proliferation and lineage programs.Breast cancer risk assessment: a non-invasive multiparametric approach to stratify patients by MMP-9 serum activity and RhoA expression patterns in circulating leucocytes.Optimal duration of adjuvant endocrine therapy: how to apply the newest data.Cancer Stem Cell Phenotypes in ER+ Breast Cancer Models are Promoted by PELP1/AIB1 Complexes.Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.High glucose and insulin enhance uPA expression, ROS formation and invasiveness in breast cancer-derived cells.Mature and progenitor endothelial cells perform angiogenesis also under protease inhibition: the amoeboid angiogenesis.Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer.Diabetes-associated dysregulated cytokines and cancer.
P2860
Q26777676-2EC36D1A-50F7-4D7D-BE52-D9E1E295D9FAQ28085413-611FC66B-0AF0-4AF2-9F22-3335DA899991Q28739536-42BEA9B4-1ABB-4058-B796-3F80E1DDEF47Q30249137-5ED88F21-4FAA-4640-B0BE-7FFD3E9066ECQ35990029-3EAD2B19-FE1E-485B-A327-ABD5BB02BC8AQ36166157-2D891214-5DCD-4383-8614-3828AEA893D9Q36379915-8D79C435-F62F-48AA-9E49-8B66FA907B32Q37056918-647D2800-532B-4D12-B5D7-41D0DAF11935Q37655098-6F366EA4-AC2A-4432-914B-C15F128AE654Q37671450-A6931FBD-4D42-4BC4-B420-55737523EE3AQ37688258-A49C25B8-FCDF-4F04-BB04-F5556D6DFE8DQ37696118-2F19316A-0BB8-44C9-9707-BEE9E280D76CQ38649391-8C86E062-4A17-4048-A424-98681EE55A48Q38690101-FF364887-51DE-4EC8-92C5-B0BEF74FF342Q38760824-7B22B48F-5063-49CF-9EA6-89E4F06709A0Q38781428-520BB030-9C2E-4651-A89C-C43C27EF1951Q38804110-5361D00B-E7E7-4868-94E8-037B9B26A661Q38908304-06922FEA-0631-4557-9898-BC1D4DCEE199Q39190318-71A77E99-2307-4DC0-8C10-2275744C5D7BQ39434447-D7CA728F-396E-4608-8DBE-25D65BDF693BQ40383860-4E133F2B-2BCE-46BE-A68B-7A78F89FEBE0Q41028891-F7D9E743-A0E8-4CFB-90BA-629AB588BD32Q41093581-FF88A573-ABB0-4370-A626-5F7A1823DA67Q41193853-EB7A19F1-FC2D-42C2-B4B7-59CDBFEC757DQ41472180-C2403597-282F-436B-94BA-9B1B0C6E0A83Q41717944-2DC7688D-13A8-4E64-939F-C68108E68FCFQ41725997-8802BA03-D0E9-49FA-BEDF-64B47DE5E651Q42364244-9BCAE32F-D3BD-4511-BE57-707C5D0DD73DQ42508717-EEC48CB1-3BC1-46BC-8EEB-C4EF9AD6F864Q42516196-714E0509-318B-49ED-A406-326415AC0A3FQ43375967-71809C67-DEE4-4272-8033-3319C019CD3EQ47327357-D56A9DBC-0C44-48B3-903C-F1C82B8D0FB8Q48245934-AB73BA1A-4495-4505-8E67-0A8C387DCC7CQ49177338-BD43F932-E1E6-4FFE-B252-A83BB37ED7C3Q49954115-21D44D01-16C0-40C3-BF78-D5AF2625556AQ51779283-2316FF3D-42BA-4736-87AB-67055C0FEC24Q53116632-7BF2BEE7-E6D1-436D-A1AC-A2FE5B852A79Q54936719-AF73F924-8FE6-46B3-AD37-ABD1A220859CQ54976480-72E35689-34C1-4766-8775-85C6EAC8A51AQ55331908-F5BF0ED9-1C54-4E1F-8733-E32470A6BAD8
P2860
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
uPA and PAI-1 as biomarkers in ...... n level-of-evidence-1 studies.
@ast
uPA and PAI-1 as biomarkers in ...... n level-of-evidence-1 studies.
@en
type
label
uPA and PAI-1 as biomarkers in ...... n level-of-evidence-1 studies.
@ast
uPA and PAI-1 as biomarkers in ...... n level-of-evidence-1 studies.
@en
prefLabel
uPA and PAI-1 as biomarkers in ...... n level-of-evidence-1 studies.
@ast
uPA and PAI-1 as biomarkers in ...... n level-of-evidence-1 studies.
@en
P2093
P2860
P921
P1476
uPA and PAI-1 as biomarkers in ...... n level-of-evidence-1 studies.
@en
P2093
Christoph Thomssen
Manfred Schmitt
Michael J Duffy
Patricia M McGowan
P2860
P2888
P356
10.1186/S13058-014-0428-4
P5008
P577
2014-08-22T00:00:00Z
P5875
P6179
1043961646